title: Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus.
abstract: OBJECTIVE
  Interferon therapy has been associated with a number of severe side effects when administered to patients with decompensated cirrhosis caused by chronic hepatitis B. The safety and potential efficacy of a low-dose, titratable regimen of interferon alfa-2b in patients with decompensated liver disease caused by chronic hepatitis B virus infection were studied.
  
  
  METHODS
  Twenty-six patients were treated at five medical centers. Five patients had Child's class A status, 15 had Child's B status, and 6 had Child's C status. Treatment was continued for 24 weeks whenever possible. Dose adjustments were made according to predefined safety criteria.
  
  
  RESULTS
  All patients with Child's A status responded with a sustained loss of serum hepatitis B virus DNA, reduction in aminotransferase activity, and clinical stabilization. Only 5 patients with Child's B (33%) and no patients with Child's C status reached similar end points. The probability of survival was greater in responders than in nonresponders (P = 0.017). Three patients each developed serious infections or greater than twofold increases in serum aminotransferase levels during therapy.
  
  
  CONCLUSIONS
  Low-dose, titratable interferon therapy is safer than previously reported regimens. Nonetheless, serious infections were observed relatively frequently, and this therapy should be reserved for individuals with mild to moderate hepatic decompensation, preferably patients with Child's A status.
authors.affiliation: Gastroenterology Section, Veterans Affairs Medical Center, St. Louis, Missouri, USA.
authors.forename: R
authors.initials: R
authors.lastname: Perrillo
authors.forename: C
authors.initials: C
authors.lastname: Tamburro
authors.forename: F
authors.initials: F
authors.lastname: Regenstein
authors.forename: L
authors.initials: L
authors.lastname: Balart
authors.forename: H
authors.initials: H
authors.lastname: Bodenheimer
authors.forename: M
authors.initials: M
authors.lastname: Silva
authors.forename: E
authors.initials: E
authors.lastname: Schiff
authors.forename: C
authors.initials: C
authors.lastname: Bodicky
authors.forename: B
authors.initials: B
authors.lastname: Miller
authors.forename: C
authors.initials: C
authors.lastname: Denham
mesh_terms: D000328:Adult; D000368:Aged; D002908:Chronic Disease; D004279:DNA, Viral / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000150:complications / Q000628:therapy* / Q000821:virology; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012074:Remission Induction; D017186:Titrimetry; D014481:United States
chemical_list: D004279:DNA, Viral; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins